NCT07824310Not yet recruitingPhase 3
Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Td Vaccines in Healthy Population Aged 9-15 Years Old in Indonesia
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
This study will evaluate the safety and immune response of a single dose of a quadrivalent human papillomavirus (HPV) vaccine when given together with a tetanus-diphtheria (Td) vaccine in healthy children and adolescents aged 9 to 15 years. The study will compare participants who receive the HPV vaccine together with the Td vaccine with those who receive the HPV vaccine alone. The study will assess whether giving the two vaccines together produces an immune response to HPV that is not lower than giving the HPV vaccine alone.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 266 (estimated)
- First submitted
- 11 Sept 2026
- Start date
- Oct 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- PT Bio Farma
- NCT number
- NCT07824310
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 266
- From Oct 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent/other trial;
- Recent treatment likely to alter immune response; 6. Pregnancy/breastfeeding;
- 7\. Abnormality/chronic disease interfering with objectives; 8. History of HPV/diphtheria/tetanus infection; 9. Previous HPV vaccination.
Other illness
- Evolving illness/fever ≥37.5°C;
- Allergy to vaccine components;
- Uncontrolled coagulopathy/blood disorder contraindicating IM injection;
Who the study is looking for
- Age 9-15 years;
- Healthy;
- Subject/parent or LAR appropriately informed and consent/assent signed;
- Willing to comply with investigator instructions and study schedule.
Age in the registry: 9 years to 15 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| RSUD Dr. Soetomo Coordinator of this site? Confirm its status | Surabaya | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.